McKesson strikes $2.25B deal to snap up Precision Medicine Group

McKesson Corporation is expanding its drug development and commercialization capacity to the tune of $2.25 billion. | The healthcare conglomerate ,which ranks eighth on the Fortune 500 list, is set to envelope privately held Precision Medicine Group into its oncology branch as part of an ongoing effort to grow it's high-margin cancer and biopharma businesses.